HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ras triggers acidosis-induced activation of the extracellular-signal-regulated kinase pathway in cardiac myocytes.

Abstract
In cardiac myocytes, sustained (3 min) intracellular acidosis activates the ERK1/2 (extracellular-signal-regulated kinase 1/2) pathway and, through this pathway, increases sarcolemmal NHE (Na+/H+ exchanger) activity [Haworth, McCann, Snabaitis, Roberts and Avkiran (2003) J. Biol. Chem. 278, 31676-31684]. In the present study, we aimed to determine the time-dependence, pH-dependence and upstream signalling mechanisms of acidosis-induced ERK1/2 activation in ARVM (adult rat ventricular myocytes). Cultured ARVM were subjected to intracellular acidosis for up to 20 min by exposure to NH4Cl, followed by washout with a bicarbonate-free Tyrode solution containing the NHE1 inhibitor cariporide. After the desired duration of intracellular acidosis, the phosphorylation status of ERK1/2 and its downstream effector p90(RSK) (90 kDa ribosomal S6 kinase) were determined by Western blotting. This revealed a time-dependent transient phosphorylation of both ERK1/2 and p90(RSK) by intracellular acidosis (intracellular pH approximately 6.6), with maximum activation occurring at 3 min and a return to basal levels by 20 min. When the degree of intracellular acidosis was varied from approximately 6.8 to approximately 6.5, maximum ERK1/2 phosphorylation was observed at an intracellular pH of 6.64. Inhibition of MEK1/2 [MAPK (mitogen-activated protein kinase)/ERK kinase 1/2) by pre-treatment of ARVM with U0126 or adenoviral expression of dominant-negative D208A-MEK1 protein prevented the phosphorylation of ERK1/2 by sustained intracellular acidosis, as did inhibition of Raf-1 with GW 5074 or ZM 336372. Interference with Ras signalling by the adenoviral expression of dominant-negative N17-Ras protein or with FPT III (farnesyl protein transferase inhibitor III) also prevented acidosis-induced ERK1/2 phosphorylation, whereas inhibiting G-protein signalling [by adenoviral expression of RGS4 or Lsc, the RGS domain of p115 RhoGEF (guanine nucleotide-exchange factor)] or protein kinase C (with bisindolylmaleimide I) had no effect. Our data show that, in ARVM, sustained intracellular acidosis activates ERK1/2 through proximal activation of the classical Ras/Raf/MEK pathway.
AuthorsRobert S Haworth, Semjidmaa Dashnyam, Metin Avkiran
JournalThe Biochemical journal (Biochem J) Vol. 399 Issue 3 Pg. 493-501 (Nov 01 2006) ISSN: 1470-8728 [Electronic] England
PMID16831126 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • 2-(2-oxo-2-((3,7,11-trimethyl-2,6,10-dodecatrienyl)oxy)aminoethyl)phosphonic acid, (2,2-dimethyl-1-oxopropoxy)methyl ester sodium
  • Cation Transport Proteins
  • Guanidines
  • Isotonic Solutions
  • Organophosphonates
  • Recombinant Fusion Proteins
  • SLC9A1 protein, human
  • Sodium-Hydrogen Exchanger 1
  • Sodium-Hydrogen Exchangers
  • Sulfones
  • Tyrode's solution
  • Ammonium Chloride
  • cariporide
  • Ribosomal Protein S6 Kinases, 90-kDa
  • Mitogen-Activated Protein Kinase 1
  • Mitogen-Activated Protein Kinase 3
  • HRAS protein, human
  • Proto-Oncogene Proteins p21(ras)
Topics
  • Acidosis (enzymology)
  • Ammonium Chloride (pharmacology)
  • Animals
  • Cation Transport Proteins (antagonists & inhibitors)
  • Cells, Cultured (drug effects, enzymology)
  • Enzyme Activation (drug effects)
  • Guanidines (pharmacology)
  • Hydrogen-Ion Concentration
  • Isotonic Solutions (pharmacology)
  • Mitogen-Activated Protein Kinase 1 (metabolism)
  • Mitogen-Activated Protein Kinase 3 (metabolism)
  • Myocytes, Cardiac (enzymology)
  • Organophosphonates (pharmacology)
  • Proto-Oncogene Proteins p21(ras) (genetics, physiology)
  • Rats
  • Recombinant Fusion Proteins (physiology)
  • Ribosomal Protein S6 Kinases, 90-kDa (metabolism)
  • Signal Transduction
  • Sodium-Hydrogen Exchanger 1
  • Sodium-Hydrogen Exchangers (antagonists & inhibitors)
  • Sulfones (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: